SELPMAKS 40 Drug name: SELPMAKS 40 Generic name: Selpercatinib Capsules

The following is the general instructions for Selpercatinib, which is for reference only. Please refer to the instructions in the drug packaging for specific use and follow the doctor's instructions.

---

Drug Name

Generic Name: Selpercatinib
Product name: SELPMAKS 40

---

Indications

Selumetinib is a targeted anticancer drug indicated for the following conditions:

1. Advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) :
   • For the treatment of adult patients with advanced or metastatic non-small cell lung cancer with confirmed RET gene fusion.
2. Advanced or metastatic RET mutation-positive medullary thyroid cancer (MTC) :
   • For the treatment of adults and children (12 years and older) with advanced or metastatic medullary thyroid cancer who have been confirmed to be RET mutation-positive.
3. Other malignancies that are RET mutation- or fusion-positive :
   • In certain specific cases, selumetinib can also be used to treat other RET mutation- or fusion-positive tumors.

---

Mechanism of action

Semetatinib is an oral small molecule RET tyrosine kinase inhibitor that can selectively target abnormal signal transduction caused by RET gene mutation or fusion, inhibit the activity of RET tyrosine kinase, and thus inhibit the proliferation and growth of tumor cells.

---

Dosage

• Recommended dose :
  • Take 120 mg orally twice a day.
• Directions :
  • May be taken with or without food. Tablets should be swallowed whole and should not be crushed, chewed or split.
• Dosage adjustments :
  • If serious adverse reactions occur, your doctor may reduce the dose or suspend treatment.
  • For patients with hepatic impairment, the dose may need to be adjusted on a case-by-case basis.

---

Precautions

1. Side Effect Monitoring :
   • Common side effects : high blood pressure, diarrhea, fatigue, nausea, constipation, loss of appetite, abnormal liver function, etc.
   • Serious side effects : QT interval prolongation, severe liver damage, lung problems (such as interstitial lung disease), etc.
2. Use in special populations :
   • Pregnant and lactating women : Contraindicated, selumetinib may cause serious harm to the fetus. Lactating women should stop breastfeeding during use.
   • Children : Safety and effectiveness have not been established, but it may be considered for use in children 12 years and older.
   • Elderly : Use with caution and may require dose adjustment based on the patient's health status.
3. Other notes :
   • Monitor liver function and electrocardiogram (particularly QT interval) regularly.
   • During treatment, if you develop severe diarrhea or liver function problems, you should seek medical attention immediately.

---

Drug interactions

• CYP3A4 inducers : such as rifampicin and St. John's wort, may reduce the efficacy of selumetinib and should be avoided in combination.
• CYP3A4 inhibitors : such as ketoconazole and erythromycin, may increase the blood concentration of selumetinib and should be used with caution.
• Other anticancer drugs : The combined use may enhance or reduce the efficacy or toxicity of selumetinib and requires close monitoring.

---

Contraindications

• Patients who are allergic to selumetinib or its excipients are contraindicated.
• It is contraindicated for pregnant and lactating women.

---

Storage conditions

• Store in a dry environment at 20°C to 25°C.
• Avoid high temperature, humidity and direct light, and the medicine should be stored out of the reach of children.

---

Important Tips

• When using selumetinib for treatment, patients should be treated under the guidance of an experienced physician.
• Perform liver function tests and electrocardiograms regularly during treatment, especially monitoring the QT interval.
• If serious adverse reactions occur (such as QT interval prolongation, abnormal liver function, or severe diarrhea), treatment should be suspended and medical attention should be sought promptly.

---

Note : If you need more detailed information or special case medication plans, please consult your doctor or pharmacist. If you have any other questions, please let me know!